Autolus Therapeutics (AUTL) Shares Up 5.6%

Autolus Therapeutics Ltd – (NASDAQ:AUTL)’s share price shot up 5.6% during mid-day trading on Thursday . The stock traded as high as $26.71 and last traded at $25.65. 810,045 shares changed hands during trading, an increase of 1,041% from the average session volume of 70,982 shares. The stock had previously closed at $24.30.

Several brokerages recently issued reports on AUTL. HC Wainwright set a $45.00 price target on Autolus Therapeutics and gave the company a “buy” rating in a research note on Wednesday, February 20th. William Blair restated a “buy” rating on shares of Autolus Therapeutics in a research note on Wednesday, April 3rd. Finally, Zacks Investment Research upgraded Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, December 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. Autolus Therapeutics presently has an average rating of “Buy” and a consensus target price of $44.00.

The company has a market cap of $1.07 billion and a PE ratio of -18.06.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Monday, February 25th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.10). The company had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $0.50 million. As a group, analysts forecast that Autolus Therapeutics Ltd – will post -2.35 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Barclays PLC acquired a new stake in Autolus Therapeutics during the fourth quarter valued at approximately $113,000. Virtus ETF Advisers LLC acquired a new stake in Autolus Therapeutics during the fourth quarter valued at approximately $312,000. Geode Capital Management LLC acquired a new stake in Autolus Therapeutics during the fourth quarter valued at approximately $322,000. Federated Investors Inc. PA acquired a new stake in Autolus Therapeutics during the third quarter valued at approximately $1,416,000. Finally, Allianz Asset Management GmbH acquired a new stake in Autolus Therapeutics during the third quarter valued at approximately $2,033,000. Hedge funds and other institutional investors own 40.55% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by WKRB News and is the sole property of of WKRB News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.wkrb13.com/2019/04/11/autolus-therapeutics-autl-shares-up-5-6.html.

About Autolus Therapeutics (NASDAQ:AUTL)

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.

Recommended Story: Marijuana Stocks Future Looks Bright

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.